FASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
Objective: We sought to highlight how our understanding of the pathophysiology of severe asthma has evolved over time and discuss the role of biomarkers in treatment advances and emerging new therapies. Data Sources: Nonsystematic PubMed literature search. Study Selection: Articles were selected based...
In recent years, novel monoclonal antibodies have been developed, which are a promising addition to existing therapy in the treatment of severe asthma with eosinophilic inflammation and Th2-driven disease. We expect that several of the new antibodies will become available for clinical practice. In ...
Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immunotherapies demonstrated...
NUCALA is indicated for the add-on treatment of patients 6+ with severe eosinophilic asthma (SEA). Not for acute bronchospasm or status asthmaticus. See all indications Learn more about the establishedsafety profileof NUCALA in SEA. Trial 2:32-week placebo-controlled study (N=576) ...
Care guide for Asthma in Children (Discharge Care). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
anti-IL-5 treatments. This might help us not only understand possiblemechanisms that contribute to the resistance to treatment in this particular asthma endotype, butalso to phenotype within severe eosinophilic asthma in order to treat our patients more eff i ciently.Keywords: asthma; severe eosi...
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2023 Dec 7:S0140-6736(23)02284-5. doi:10.1016/S0140-6736(23)02284-5...
What is severe eosinophilic asthma?Eosinophilic Asthma - A Severe Asthma Subtype:There are six different asthma types with four different severity staging classifications. Eosinophilic asthma is considered to be a severe variant of asthma requiring treatment and medical follow-up....
Let’s get to it withNUCALA. NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. Learn about taking NUCALA at home Info about NUCALA sent straight to my inbox? Sign me up. ...